共 50 条
- [31] Efficacy and Safety of Ibrutinib (IBR) after Venetoclax (VEN) Treatment in IBR-Naive Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Follow-up of Patients from the MURANO StudyBLOOD, 2018, 132Greil, RichardFraser, GraemeLeber, BrianMarks, ReinhardQuaresmini, GiuliaMiddeke, Jan MoritzSemenzato, GianpietroSchary, WilliamBoyer, MichelleBreuleux, MadlainaCrompton, NoelleHumphrey, KathrynMarlton, Paula
- [32] Long-Term Outcomes and Safety of Continuous Lenalidomide Plus Dexamethasone (Len plus Dex) Treatment in Patients (Pts) with Relapsed or Refractory Multiple Myeloma (RRMM)BLOOD, 2011, 118 (21) : 1263 - 1263Dimopoulos, Meletios AthanasiosHussein, MohamadSwern, Arlene S.Weber, Donna M.
- [33] Venetoclax and Ibrutinib for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL)-15-Month Safety, Response and MRD Evaluation: Third Interim Analysis from the Phase II Vision HO141 TrialBLOOD, 2019, 134Niemann, Carsten UtoftDubois, JulieKersting, SabinaEnggaard, LisbethVeldhuis, Gerrit J.Mous, RogierMellink, ClemensDobber, Johan A.Poulsen, Christian BjornFrederiksen, HenrikJanssens, AnnSchjodt, IdaDompeling, Ellen C.Ranti, JuhaMattsson, MattiasBellido, MarTran, Hoa T.Nasserinejad, KazemLevin, Mark-DavidKater, Arnon P.
- [34] Time-Limited Venetoclax and Ibrutinib for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) Who Have Undetectable MRD - Primary Analysis from the Randomized Phase II Vision HO141 TrialBLOOD, 2021, 138Niemann, Carsten UtoftDubois, JulieBrieghel, ChristianKersting, SabinaEnggaard, LisabethVeldhuis, Gerrit J.Mous, RogierMellink, ClemensDobber, Johan A.Poulsen, Christian BjornFrederiksen, HenrikJanssens, AnnSchjodt, IdaDompeling, Ellen C.Ranti, JuhaMattson, MattiasBellido, MarNasserinejad, KazemHoa Thi Thuyet TranLevin, Mark-DavidKater, Arnon P.
- [35] Durability of Responses on Continuous Therapy and Following Drug Cessation with Venetoclax and Rituximab: Long-Term Follow-up Analysis of a Phase 1b Study in Patients with Relapsed CLLBLOOD, 2019, 134Brander, Danielle M.Seymour, John F.Kipps, Thomas J.Ma, ShuoAnderson, Mary AnnChoi, Michael Y.Humphrey, KathrynAl Masud, AbdullahNandam, RubyJacobson, AmandaRoberts, Andrew W.
- [36] Using Peripheral Blood (PB) Measurable Residual Disease (MRD) Levels to Predict <0.01% Bone Marrow Disease (BM uMRD4): Identification of Effective PB Targets for CLL Treatment Cessation in the Ibrutinib plus Venetoclax Arm of the FLAIR TrialBLOOD, 2023, 142Rawstron, AndyWebster, NicholaDalal, Suritade Tute, Ruth M.Bell, SueCairns, David AllanGirvan, SeanGreatorex, NatashaHockaday, AnnaJackson, SharonPhillips, DavidStones, DavidAllsup, DavidBloor, Adrian John CliftonSarma, AnitaVarghese, Abraham MullasserilMunir, TalhaHillmen, Peter
- [37] Characterization of the Long-Term Efficacy and Safety of Duvelisib Monotherapy in Patients with Relapsed/Refractory CLL/SLL on Treatment for > 2 Years across 4 Clinical StudiesBLOOD, 2018, 132Flinn, Ian W.Montillo, MarcoNagy, ZsoltGasztonyi, ZoltanDavids, Matthew S.Geissler, KlausRoca, Jose J. RifonBerkhan, LeanneOffner, FritzLe, NgocDiepLustgarten, StephanieDelgado, Julio
- [38] Minimal residual disease-guided stop and start of venetoclax plus ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia (HOVON141/VISION): primary analysis of an open-label, randomised, phase 2 trialLANCET ONCOLOGY, 2022, 23 (06): : 818 - 828Kater, Arnon P.Levin, Mark-DavidDubois, JulieKersting, SabinaEnggaard, LisbethVeldhuis, Gerrit J.Mous, RogierMellink, Clemens H. M.van der Kevie-Kersemaekers, Anne-Marie F.Dobber, Johan A.Poulsen, Christian B.Frederiksen, HenrikJanssens, AnnSchjodt, IdaDompeling, Ellen C.Ranti, JuhaBrieghel, ChristianMattsson, MattiasBellido, MarTran, Hoa T. T.Nasserinejad, KazemNiemann, Carsten U.
- [39] Monosomy 13 in metaphase spreads is a predictor of poor long-term outcome after bortezomib plus dexamethasone treatment for relapsed/refractory multiple myelomaINTERNATIONAL JOURNAL OF HEMATOLOGY, 2012, 95 (05) : 516 - 526Kiyota, MikiKobayashi, TsutomuFuchida, ShinichiYamamoto-Sugitani, MioOhshiro, MuneoShimura, YujiMizutani, ShinsukeNagoshi, HisaoSasaki, NanaNakayama, RyukoChinen, YoshiakiSakamoto, NatsumiUchiyama, HitojiMatsumoto, YosukeHoriike, ShigeoShimazaki, ChihiroKuroda, JunyaTaniwaki, Masafumi
- [40] Monosomy 13 in metaphase spreads is a predictor of poor long-term outcome after bortezomib plus dexamethasone treatment for relapsed/refractory multiple myelomaInternational Journal of Hematology, 2012, 95 : 516 - 526Miki KiyotaTsutomu KobayashiShinichi FuchidaMio Yamamoto-SugitaniMuneo OhshiroYuji ShimuraShinsuke MizutaniHisao NagoshiNana SasakiRyuko NakayamaYoshiaki ChinenNatsumi SakamotoHitoji UchiyamaYosuke MatsumotoShigeo HoriikeChihiro ShimazakiJunya KurodaMasafumi Taniwaki